Pyrazolyl nicotinamides and pyrimidine carboxamides as CAMK2 inhibitors

Novel pyrazolyl nicotinamides and pyrimidine carboxamides serve as effective inhibitors of CAMK2 kinases, addressing the inadequacies of current treatments for conditions like heart failure and cardiac arrhythmias, offering therapeutic benefits across multiple disorders.

WO2026112045A1PCT designated stage Publication Date: 2026-05-28BRISTOL MYERS SQUIBB CO
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
BRISTOL MYERS SQUIBB CO
Filing Date
2025-11-18
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Current treatments for diseases associated with Calcium calmodulin dependent protein kinase 2 (CAMK2) kinases, such as heart failure, fibrosis, and cardiac arrhythmias, are inadequate, and there is a need for more effective inhibitors to manage these conditions.

Method used

Development of novel pyrazolyl nicotinamides and pyrimidine carboxamides that act as selective inhibitors of CAMK2 isoforms, including CAMK2D, CAMK2A, CAMK2B, and CAMK2G, which can be used in pharmaceutical compositions to treat these diseases.

Benefits of technology

The compounds effectively inhibit CAMK2 activity, providing therapeutic benefits in treating conditions like heart failure, fibrosis, and cardiac arrhythmias, with potential applications in other disorders including diabetes, asthma, and anxiety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000006_0002
    Figure IMGF000006_0002
Patent Text Reader

Abstract

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2), which may be used as medicaments for the treatment of heart failure, and related diseases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • 2, 6-diamino-pyrimidin- 5-YL-carboxamides as SYK or JAK kinases inhibitors

    WO2009145856A1

  • Fused heteroaryl compounds and their use as camkii inhibitors

    WO2022067082A1

  • Heterocyclic compounds as kinase inhibitor and uses thereof

    WO2022162606A1

  • TYK2 inhibitors and compositions and methods thereof

    WO2023109954A1